Article Text

Download PDFPDF
  1. Richard Nicholas1,
  2. Jerome Hanna2
  1. 1 Imperial College Healthcare NHS Trust
  2. 2 Biogen, Maidenhead, UK


Introduction The Tysabri® Observational Program (TOP) is a 10-year, ongoing, global open-label study in clinical practice settings enrolling natalizumab-treated patients with relapsing-remitting multiple sclerosis (MS).

Methods Annualized relapse rates (ARRs) pre- and post-natalizumab were compared.

Results As of 1 May 2015, 134 UK TOP patients had received a median (range) of 43 (1 64) doses. Median disease duration was 5.3 years, with 3.15 mean relapses in the 2 years pre-natalizumab. Among all patients, 63.4% had prior MS therapy (mean duration 1.8 years). Prior treatments included interferon betas (IFN; n=66), glatiramer acetate (GA; n=34), fingolimod (n=1), and immunosuppressants (n=3). Mean time between stopping prior treatment and starting natalizumab was 4–6 months. ARR decreased from 2.21 pre-natalizumab to 0.23 on treatment (89.6% reduction; p<0.0001). Similarly, in natalizumab patients previously treated with IFN and GA, ARR decreased from 2.03 to 0.21 (89.7% reduction) and from 2.00 to 0.23 (88.5% reduction), respectively (p<0.0001). No progressive multifocal leukoencephalopathy cases or new safety signals were identified in this cohort.

Conclusions Notwithstanding the inherent limitations of this small-cohort analysis, natalizumab reduces relapse rate post IFN or GA.

Supported by Biogen. Disclosures: RN: grant and conference travel support from Biogen; JH: employee of and holds stock/stock options in Biogen.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.